Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.

Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L; Danish Pneumococcal Surveillance Collaboration Group 2009-2010.

Vaccine. 2012 Jun 6;30(26):3944-50. doi: 10.1016/j.vaccine.2012.03.060. Epub 2012 Apr 11.

PMID:
22504662
3.

Global prevailing and emerging pediatric pneumococcal serotypes.

McIntosh ED, Reinert RR.

Expert Rev Vaccines. 2011 Jan;10(1):109-29. doi: 10.1586/erv.10.145. Review.

PMID:
21162625
4.

Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.

Madhi SA, Cohen C, von Gottberg A.

Vaccine. 2012 Sep 7;30 Suppl 3:C21-7. doi: 10.1016/j.vaccine.2012.05.055. Review.

PMID:
22939016
5.

Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.

Dagan R.

Clin Microbiol Infect. 2009 Apr;15 Suppl 3:16-20. doi: 10.1111/j.1469-0691.2009.02726.x. Review.

6.

Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region.

Lin TY, Shah NK, Brooks D, Garcia CS.

Vaccine. 2010 Nov 10;28(48):7589-605. doi: 10.1016/j.vaccine.2010.07.053. Epub 2010 Aug 1. Review.

PMID:
20674872
7.

Pneumococcal serotype evolution in Western Europe.

Tin Tin Htar M, Christopoulou D, Schmitt HJ.

BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. Review.

8.

[Heptavalent-pneumococcal conjugate vaccine (Prevenar). Differences in effectiveness between populations].

Guevara M, Barricarte A, Pérez B, Arriazu M, García Cenoz M, Castilla J.

An Sist Sanit Navar. 2008 May-Aug;31(2):171-92. Review. Spanish.

9.

Epidemiological changes after PCV7 implementation in Italy: perspective for new vaccines.

Ansaldi F, de Florentis D, Canepa P, Bandettini R, Diana MC, Martini M, Durando P, Icardi G.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:211-6. doi: 10.4161/hv.7.0.14602. Review.

PMID:
21546795
10.

Epidemiology of invasive pneumococcal disease in the Arabian Peninsula and Egypt.

Shibl A, Memish Z, Pelton S.

Int J Antimicrob Agents. 2009 May;33(5):410.e1-9. doi: 10.1016/j.ijantimicag.2008.08.012. Epub 2008 Oct 30. Review.

PMID:
18976887
11.

Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.

Dinleyici EC, Yargic ZA.

Expert Rev Vaccines. 2009 Aug;8(8):977-86. doi: 10.1586/erv.09.68. Review.

PMID:
19627181
12.

Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.

Balsells E, Guillot L, Nair H, Kyaw MH.

PLoS One. 2017 May 9;12(5):e0177113. doi: 10.1371/journal.pone.0177113. eCollection 2017. Review.

13.

Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization.

Loo JD, Conklin L, Fleming-Dutra KE, Knoll MD, Park DE, Kirk J, Goldblatt D, O'Brien KL, Whitney CG.

Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S161-71. doi: 10.1097/INF.0000000000000084. Review.

14.

Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects.

Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL.

Vaccine. 2013 Dec 17;32(1):133-45. doi: 10.1016/j.vaccine.2013.05.005. Epub 2013 May 16. Review.

PMID:
23684824
15.

The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.

Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, Sprenger R, Bonnet E.

Adv Ther. 2013 Feb;30(2):127-51. doi: 10.1007/s12325-013-0007-6. Epub 2013 Feb 7. Review.

PMID:
23397399
16.

Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake.

Grabenstein JD, Weber DJ.

Clin Infect Dis. 2014 Mar;58(6):854-64. doi: 10.1093/cid/cit800. Epub 2013 Dec 15. Review.

PMID:
24344141
17.

Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine.

Durando P, Alicino C, De Florentiis D, Martini M, Icardi G.

J Prev Med Hyg. 2012 Jun;53(2):68-77. Review.

PMID:
23240163
18.

Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines.

Falup-Pecurariu O.

Biomed J. 2012 Nov-Dec;35(6):450-6. doi: 10.4103/2319-4170.104409. Review.

19.

Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children.

Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE, Goldblatt D, O'Brien KL, Whitney CG.

Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S109-18. doi: 10.1097/INF.0000000000000078. Review.

20.

Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.

Tan TQ.

Clin Microbiol Rev. 2012 Jul;25(3):409-19. doi: 10.1128/CMR.00018-12. Review.

Supplemental Content

Support Center